A meta analysis study found that both PD-L1 inhibitors and PD-1 inhibitors plus chemotherapy as first-line treatment could provide a significant improvement of survival time compared with chemotherapy alone for advanced SCLC patients (12). The gene discussed is PDCD1; the disease is small cell lung carcinoma.